

## SAMPLE CODING

### Alveolar Soft Part Sarcoma (ASPS)

TYPE	CODE	DESCRIPTION
Diagnosis: ICD-10-CM	C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
	C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
	C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
	C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
	C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
	C49.3	Malignant neoplasm of connective and soft tissue of thorax
	C49.4	Malignant neoplasm of connective and soft tissue of abdomen
	C49.5	Malignant neoplasm of connective and soft tissue of pelvis
	C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	
Drug: HCPCS	J9022	Injection, atezolizumab, 10 mg
<b>HCPCS: Modifier*</b> <b>Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.</b>	JW	Drug amount discarded/not administered to any patient
	JZ	Zero drug amount discarded/not administered to any patient

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

\*The JW modifier is required on claims for all single-dose container or single-use drugs when an amount is discarded. The JZ modifier is required to be used as of July 1, 2023. For more information on the JW and JZ modifiers, visit [CMS.gov](https://www.cms.gov).

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

for **TECENTRIQ<sup>®</sup>**  
(atezolizumab)

Alveolar Soft Part Sarcoma (ASPS) (cont)

TYPE	CODE		DESCRIPTION
	10-digit	11-digit	
<b>Drug: NDC</b>  <b>Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.</b>	50242-917-01	50242-0917-01	1200 mg/20 mL single-dose vial
	50242-918-01	50242-0918-01	840 mg/14 mL single-dose vial
	96413		Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
<b>Administration procedures: CPT</b>	96415		Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
	96417		Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

TECENTRIQ<sup>®</sup> is a registered trademark of Genentech, Inc.

Please see full [Prescribing Information](#) for Important Safety Information.